| abstract |
Provided herein are methods of treating patients with a combination of a transcription inhibitor (e.g., a STAT3 inhibitor) and an immune checkpoint blockade therapy (e.g., anti- PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy). The patient may have a proliferative disease, such as cancer or psoriasis. The patient may have a pathogenic infection. |